Overview
The purpose of this study is:
- To evaluate the efficacy of Songling Xuemaikang Capsules(SLXMKC) with grade 1 hypertension.
- To reveal the potiential effects of SLXMKC on vascular function and structure of patients with grade 1 hypertension.
- To explore the underlying mechanisms of the therapeutic effects of SLXMKC on the intervention of grade 1 hypertension.
Eligibility
Inclusion Criteria:
- Age between 35-65 years old, male or female;
- Grade 1 essential hypertension;
- Taking no antihypertensive drugs or taking antihypertensive drugs irregularly in the past ;
- Sign the informed consent;
Exclusion Criteria:
- Significant liver and kidney dysfunction, ALT and AST upper the twice of normal range, Scr≥2.0mg/dl, eGFR<60ml/(min·1. 73m2);
- Gastrointestinal diseases, which may affect drug absorption;
- Be allergic to the clinical trial medicine;
- Pregnant or breastfeeding women, men who plan to give birth within half a year;
- Combined with other serious primary diseases or malignant tumors;
- Hyperlipidemia with or without taking lipid-lowering drugs;
- Combined with left ventricular hypertrophy, ABI < 0.9, CIMT ≥ 0.9mm or atherosclerotic plaque;
- Hypertensive comorbidities (cerebrovascular disease, other cardiovascular diseases, renal disease, peripheral artery disease, retinopathy, diabetes);
- Other serious conditions in which is not fit for the study.